N-myristoyltransferase (NMT) attaches the fatty acid myristate to the N-terminal glycine of proteins to sort them into soluble and membrane-bound fractions. Function of the energy-sensing AMP-activated protein kinase, AMPK, is myristoylation dependent. In rheumatoid arthritis (RA), pathogenic T cells shift glucose away from adenosine tri-phosphate production toward synthetic and proliferative programs, promoting proliferation, cytokine production, and tissue invasion. We found that RA T cells had a defect in NMT1 function, which prevented AMPK activation and enabled unopposed mTORC1 signaling.
T lymphocytes are key pathogenic effector cells in RA 1, 2 . In the inflamed joint, CD4 + T cells promote lymphoid neogenesis, autoantibody production, macrophage and osteoclast activation, and pannus formation. The organotropism of RA may reflect autoantigen availability, but recent data indicate cell-intrinsic abnormalities in RA T cells that foster tissue-invasive and proinflammatory behavior 3 .
A key feature of RA T cells is the reprogramming of cellular metabolism, which redirects energy sources toward a cell-building program 4, 5 . RA T cells transcriptionally repress 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) 6 and upregulate glucose-6-phosphate dehydrogenase (G6PD) 7 , shifting glucose away from glycolysis and ATP production to the pentose phosphate pathway and biosynthesis 7, 8 . RA T cells are low in ATP, pyruvate, and reactive oxygen species (ROS), but accumulate the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), acetylcoenzyme A (-CoA), and fatty acids 5, 7 . Low availability of ROS prevents activation of ataxia telangiectasia mutated (ATM) 9 , impairs DNA repair, and, together with deficient nuclease MRE11A 10 , accelerates T cell aging.
Favoring anabolic over catabolic conditions leads to a tissueinvasive, hypermobile, pro-inflammatory phenotype driving chronic-destructive tissue inflammation 11 . Excess acetyl-CoA and NADPH promote lipogenesis 5 and lipid droplet accumulation, supplying building blocks for membranes. Comparable to tumor cell invadosomes, RA T cells form membrane ruffles, become hypermobile, and rapidly intrude into tissue sites to organize inflammatory infiltrates. Lipid droplets accumulate as a result of insufficient mitochondrial β -oxidation, ordinarily triggered in energy-oversupplied cells 12 . Lipid accumulation in ATP low conditions breaks the bioenergetics rule that the energy-sensing 5′ -AMPK registers low ADP/AMP concentrations, switches on ATP production, and halts ATP consumption 13, 14 . To restore energy homeostasis, decreasing ATP should result in reduced lipid synthesis, mTORC1 deactivation, and proliferative arrest. Instead, increased mitochondrial biogenesis should provide ATP, ROS, and metabolic intermediates fueling cataplerotic reactions 15 . The coexistence of lipogenesis and ATP deficiency in RA T cells implies a fundamental abnormality in energy sensing and use.
On sensing AMP, AMPK complexes with AXIN-LKB1, translocates to lysosomal surfaces, and assembles into the v-ATPase-Ragulator-AXIN/LKB1-AMPK super-complex, where AMPKα -Thr172 is phosphorylated by LKB1 (ref. 16 ). In addition, AMPK monitors glucose availability independently of changes in adenine nucleotides 17, 18 . Once activated, AMPK directs glucose-sensitive metabolic checkpoints and mitochondrial metabolism to support effector T cell bioenergetics and viability 13, 19 . The mammalian target of rapamycin (mTOR) integrates growth factor and nutrient signals for biosynthetic pathways and suppresses catabolic processes, programing T cell differentiation into functional lineages [20] [21] [22] . AMPK and mTORC1 share the lysosomal v-ATPase-Ragulator complex as an activator 16, 23 , interconnecting the AMPK and mTORC1 systems. Under conditions of energy shortage, AMPK phosphorylates Raptor and TSC2, thereby inactivating mTORC1 (ref. 13, 24 ).
Localization of the v-ATPase-Ragulator-AXIN/LKB1-AMPK super-complex to lysosomal membranes requires membranous anchoring, for which the C14-fatty acid myristic acid is covalently attached to AMPKβ 1 and β 2 (ref. 25 ). N-myristoylation is necessary for AMPK activation at lysosomal surfaces where the hydrophobic myristoyl group is buried in the phospholipid biolayer 25 . N-myristoylation is a co/post-translational protein-lipid modification catalyzed by N-myristoyltransferase (NMT) 26 . The two Articles NATuRe IMMuNOLOgy isozymes NMT1 and NMT2 are functionally non-redundant 26, 27 . NMT1 is critical for tumor cell proliferation, early mouse development, and proper monocytic differentiation of mouse bone marrow cells [27] [28] [29] .
Given the resistance of RA T cells to activate catabolic processes despite low ATP concentrations, we examined activation, partitioning, and subcellular localization of the energy sensor AMPK. To understand trafficking and subcellular distribution of AMPK, we focused on its myristic acid tail that confers membrane localization. We found that RA T cells have a defect in NMT1 function, disrupting AMPK's lipidic modification. Loss-of-function and gainof-function experiments connected NMT1 to T cell differentiation, but NMT1 controlled disease-inducing T cell functions in a humanized mouse model of synovitis. Mechanistic studies linked NMT1 deficiency to a defect in lysosomal recruitment of AMPK. Impaired AMPK activation endowed RA T cells with unopposed mTORC1 activation and biased them to differentiate into pro-inflammatory effector cells. Two interventions corrected the AMPK-dependent functional abnormalities in RA T cells; NMT1 overexpression and drug-induced AMPK activation; adding interference with protein co/post-translational modification and trafficking as potential antiinflammatory strategies.
Results

NMT1 deficiency in RA CD4 T cells.
CD4 + T cells from RA patients are prematurely aged, metabolically reprogrammed, tissue-invasive, and pro-inflammatory 5, 7, 30 . To examine whether the trafficking, membrane association, and subcellular localization of proteins is intact, we compared protein myristoylation in patient-derived and healthy control CD4 + T cells. We purified CD4 + CD45RA + T cells from peripheral blood mononuclear cells (PBMCs) and differentiated them into effector cells by anti-CD3/CD28 bead stimulation for 72 h. Isolated CD4 + CD45RA + populations had no significant contamination with stem-like memory T cells; CD95 + interferon-γ (IFN-γ )-producing CD4 + T cells were distinctly infrequent. Amounts of myristoylated proteins were 45% lower in stimulated CD4 + RA T cells than in controls ( Fig. 1a,b ). Concentrations of intracellular free fatty acids, including the myristoylation substrate myristic acid, were even higher in RA T cells, excluding substrate availability as the limiting factor ( Fig. 1c ). To better understand the myristoylation defect, we quantified protein expression of NMT1 in CD4 + T cells from four patient cohorts (RA, psoriatic arthritis (PsA), systemic lupus erythematosus (SLE), granulomatosis with polyangiitis (GPA)) and age-matched controls ( Fig. 1d,e ). Healthy T cells and PsA, SLE, and GPA T cells had indistinguishable NMT1 protein expression; in RA T cells, the enzyme was reduced up to 50% of controls. The NMT1 lo status in RA T cells was confirmed by immunoblotting ( Fig. 1f,g) . In contrast, NMT2 expression was indistinguishable in RA and control T cells ( Supplementary  Fig. 1a ). NMT1-specific transcripts were not different in RA and control T cells ( Supplementary Fig. 1b ), assigning reduced NMT1 expression to post-translational events. In a cohort of 24 RA patients, NMT1 protein expression in activated CD4 + T cell correlated inversely with clinical disease activity ( Fig. 1h ).
To examine NMT1 expression in different immune cell populations, we applied multicolor flow cytometry in PBMCs from RA and PsA patients ( Supplementary Fig. 1c -h). Low NMT1 expression was a feature of naive CD4 + CD45RA + T cells, memory CD4 + CD45RA -T cells, and CD19 + B cells. CD8 + CD45RA + and CD8 + CD45RA -T cells as well as CD14 + monocytes were unaffected.
To test the hypothesis that NMT1 regulates T cell effector functions, we chose a gain-of-function and loss-of-function approach. NMT1 was restored in NMT1 lo RA T cells by transfection with an NMT1 overexpression construct ( Supplementary Fig. 2a and Fig. 2a-f ). NMT1 in healthy T cells was partially silenced with siRNA ( Supplementary Fig. 2b and Fig. 2g -l). To determine the frequencies of pro-inflammatory T H 1 and T H 17 cells, we measured the expression of the lineage-determining transcription factors T-bet and RORγ t and the cytoplasmic stores for IFN-γ and interleukin 17 (IL-17). The T H 2-associated transcription factor GATA-3 served as a control. RA CD4 + T cells typically deposit neutral lipid droplets 5 . We therefore quantified cellular neutral lipid content by Bodipy 493/503 staining ( Supplementary Fig. 3a ). NMT1 overexpression in RA T cells reduced T-bet and RORγ t expression and diminished IFN-γ + and IL-17 + T cell frequencies ( Fig. 2a-d ), but left GATA-3 unaffected ( Fig. 2e ). Neutral fatty acids declined significantly ( Fig. 2f and Supplementary Fig. 3b ). NMT1 loss promptly induced T-bet and RORγ t expression and forced T cells towards T H 1 and T H 17 differentiation ( Fig. 2g-j) . GATA-3 expression was unaffected ( Fig. 2k ), but cytoplasmic lipid droplets increased ( Fig. 2l and Supplementary Fig. 3c ).
Given the distinguishing metabolic signature of RA T cells 3 , we explored whether metabolic signals can alter NMT1 protein expression ( Supplementary Fig. 4 ). We screened the effect of a series of metabolic interventions and measured NMT1 and NMT2 protein expression cytometrically. The myristoylating enzymes proved insensitive to changing metabolic conditions in and around the T cells. In summary, protein myristoylation in RA T cells is impaired; attributable to defective function of NMT1.
N-myristoylation protects against synovial inflammation.
To investigate whether and how protein myristoylation affects inflammatory disease, we made use of a humanized mouse model in which synovitis is induced in engrafted human synovial tissue after adoptive transfer of human PBMCs 5,10 ( Supplementary Fig. 5a ). After synovitis induction, explanted tissues were analyzed for gene expression profiles and tissue-residing cells. Synovial grafts from chimeras injected with control RA CD4 + CD45RO -T cells developed aggressive tissue inflammation ( Fig. 3a ) with dense T cell infiltrates ( Fig. 3a,b ) and about 60% of tissue-resident T cells producing IFN-γ ( Fig. 3c ). Enforced overexpression of NMT1 was strongly anti-inflammatory; the density of T cell infiltrates fell by 50% and the frequencies of IFN-γ -producing T cells declined by 35% ( Fig. 3b ,c). Tissue transcriptome analysis revealed marked suppression of inflammatory markers (TBX21, RORC, IFNG, IL17A, TNF), whereas GATA3, IL4 and FOXP3 remained unaffected ( Fig. 3d ).
Conversely, healthy CD4 + CD45RO -T cells rendered NMT1 lo before adoptive transfer gained inflammatory capacity ( Fig. 3e -h). Histologic evaluation revealed denser inflammatory infiltrates after NMT1 knockdown ( Fig. 3e ). Frequencies of tissue-invading T cells and tissue-residing IFN-γ + T cells increased by about twofold (Fig. 3f,g) . Tissue transcriptome analysis yielded unaffected expression of GATA3, IL4 and FOXP3, but marked induction of inflammatory molecules (Fig. 3h ). Specifically, mRNA expression of TRB, T H 1 and T H 17 lineage markers and the inflammatory cytokine TNF were upregulated by NMT1 knockdown.
The anti-inflammatory effect of NMT1 overexpression and the pro-inflammatory effects of NMT1 loss were confirmed in human-synovium-NSG mice reconstituted with transfected PBMCs ( Supplementary Fig. 5b -i). Together, these data identified NMT1 as a tissue-protective enzyme, controlling inflammatory properties of effector T cells.
NMT1 lo T cells insufficiently phosphorylate AMPKα.
Myristoylation is a lipid modification of proteins, changing their physical properties and their subcellular distribution and adding diversity to the proteome 26 . Due to the membrane targeting effects of the myristic acid tail, signaling pathways occurring at membrane surfaces are particularly dependent on lipidic modification. Considering the metabolic reprogramming of NMT1 low RA T cells, we explored whether AMPK, known to be myristoylated at its β -subunit N-terminus 25 , is functionally affected by NMT1 deficiency.
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We first examined whether AMPK signaling is intact in RA T cells. RA T cells had lower concentrations of ATP, accumulated AMP, and had increased ratios of ADP/ATP and AMP/ATP ( Fig. 4a-d ). Rising ratios should trigger AMPKα phosphorylation and enzyme activation 14, 17 . Phosflow examination of RA, PsA and control T cells for p-AMPKα (Thr172) demonstrated robust phosphorylation in healthy and PsA T cells, but low abundance of p-AMPKα in RA T cells ( Fig. 4e,f) . Overall, fluorescence intensity signals for p-AMPKα were twofold higher in healthy versus RA T cells. Immunoblotting experiments confirmed that protein concentrations of AMPKα , β and γ were similar in healthy, PsA, and RA T cells, but RA T cells failed to phosphorylate AMPKα to the same degree as controls ( Fig. 4g,h) . AMPK initiates inhibitory phosphorylation of acetyl-CoA carboxylase, an upstream enzyme in the . Healthy individuals (n = 9); RA (n = 9); PsA (n = 9); SLE (n = 6); GPA (n = 6). One-way analysis of variance (ANOVA) and post-ANOVA pair-wise two-group comparisons conducted with Tukey's method. f,g, Immunoblotting for NMT1 protein in activated CD4 + T cells. Representative immunoblots and quantification from six individuals in each group. Oneway ANOVA and post-ANOVA pair-wise two-group comparisons conducted with Tukey's method (NS, not significant). h, Correlation of clinical disease activity (measured by CDAI) and NMT1 protein expression in CD4 + T cells determined by flow cytometry in n = 24 RA patients. Spearman correlation coefficient is shown. ***P < 0.001.
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NATuRe IMMuNOLOgy lipogenic program. By immunoblotting, p-acetyl-CoA carboxylase was detectable in control T cells, but essentially absent in RA T cells ( Supplementary Fig. 6a ). Quantification of mRNA transcripts for the AMPK complex components revealed intact transcription of all elements in RA T cells ( Supplementary Fig. 6b ), suggesting that the defect in AMPK activation occurs post-transcriptionally.
Second, we quantified myristoylated AMPKβ protein using click chemistry and immunoblotting ( Fig. 4i ). Compared with healthy controls and PsA patients, RA T cells were essentially deficient in myristoylated AMPKβ . We confirmed the myristoylation defect by single-cell analysis. Applying click chemistry, we quantified the colocalization signal for myristoylated protein and AMPKβ . AMPKβ localized to the cytoplasm of healthy, PsA, and RA T cells, with similar expression intensities (Fig. 4j ). The overall load of myristoylated protein was markedly lower in RA T cells ( Fig. 4j,k) . Signal intensities for AMPK-myristoylated protein colocalization were 7.7-fold higher in control than in RA T cells ( Fig. 4j,k) .
To understand how NMT1 affects AMPKβ myristoylation, we applied a loss-of-function and a gain-of-function approach 
NATuRe IMMuNOLOgy ( Fig. 5a-d ). NMT1 knockdown in healthy T cells left AMPKβ expression unaffected, but markedly suppressed lipid-modified proteins (Fig. 5a,b ). AMPKβ /myristoylated protein colocalization declined significantly, mimicking conditions in RA T cells. Conversely, NMT1 overexpression in NMT1 lo RA T cells restored protein myristoylation with AMPKβ amounts unchanged ( Fig. 5c,d) . Immunoblotting experiments confirmed that the concentrations of myristoylated AMPKβ protein were NMT1dependent ( Fig. 5e,f ). NMT1 silencing in healthy T cells markedly reduced the amount of myristoylated AMPKβ and, vice versa, forced overexpression of NMT1 in RA T cells rescued formation of myristoylated AMPKβ . 
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We verified these results by genetic manipulation of NMT1 in T cells using phosphorylation of AMPKα as a readout of kinase activation. Flow cytometry of p-AMPKα confirmed the reduction of phosphorylated AMPKα in healthy T cells after NMT1 knockdown (Fig. 5g,h) . Conversely, phosphorylated AMPKα increased significantly in RA T cells transfected with an NMT1 expression vector (Fig. 5i,j) . Together, these studies identified NMT1 as a critical regulator of AMPK function and implicated the process of co/posttranslational lipid modification in the failed activation of AMPK in energy-starved RA T cells. 
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kinase's subcellular localization. Lysosomes were identified by immunostaining for lysosomal-associated membrane protein 1 (LAMP1); AMPK localization was visualized with AMPKα -specific antibodies. Staining intensities for LAMP1 and AMPKα were similar in RA and healthy T cells (Fig. 6a) . In healthy T cells, AMPKα colocalized with lysosomal LAMP1. In contrast, RA T cells had significantly reduced LAMP1/AMPKα colocalization ( Fig. 6a,b) .
To relate the loss of lysosomal AMPK recruitment in RA T cells to NMT1 deficiency, we rendered healthy T cells NMT1 lo by silencing ( Fig. 6c,d) . Alternatively, we attempted to rescue lysosomal relocation of AMPK in RA T cells by overexpressing NMT1 (Fig. 6e,f) . Repression of NMT1 in healthy T cells had no effect on LAMP1 or AMPKα expression intensity (Fig. 6c ). However, AMPK's subcellular distribution changed markedly, no longer overlapping with perinuclear lysosomes (Fig. 6c,d) . Colocalization of the LAMP1 and AMPKα signal in NMT1 siRNA-transfected T cells resembled results in RA T cells. NMT1 overexpression did not change the signal intensity for LAMP1 or AMPKα , but moved the kinase into LAMP1 + sites (Fig. 6e,f) . RA T cells with forced NMT1 overexpression 
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Abnormalities in AMPK's lysosomal recruitment was confirmed by immunoblotting experiments (Fig. 6g,h) . Lysosomes were isolated and AMPKα , mTOR and LAMP1 were quantified in the lysosomal fraction and whole cell lysate by immunoblotting. Lysosomal AMPKα loading was low in RA compared with healthy T cells (Fig. 6g ). Control and RA T cells had similar amounts of lysosomal mTOR ( Fig. 6g and Supplementary Fig. 7a ). NMT1 knockdown reduced AMPKα in the lysosomal fraction of healthy T cells (Fig. 6h ), but did not affect the amount of lysosomal mTOR. To examine whether AMPK determines mTOR loading/retention on the lysosomal surface, we silenced AMPKα in healthy T cells and quantified mTOR in the whole cell and lysosomal fractions. Knockdown of AMPKα left lysosomal mTOR unaffected ( Supplementary Fig. 7b,c) . Overall, these data confirmed the crucial role of NMT1 in regulating AMPK trafficking between subcellular compartments and mechanistically linked the failure of AMPK activation in RA T cells to its displacement from lysosomal membranes.
NMT1 regulates mTORC1 activation in RA T cells. Regulation of both AMPK and mTORC1 by the lysosomal v-ATPase-Ragula-
tor complex provides a powerful switch between catabolism and anabolism 16 .
To investigate the status of the mTORC1 signaling pathway, we quantified the phosphorylation of S6 kinase 1 (S6K1) and S6 ribosomal protein (S6RP). Flow cytometry revealed markedly higher phosphorylated S6RP (p-S6RP) in RA T cells (Fig. 7a,b) , which we verified by immunoblotting, which demonstrated higher concentrations of p-S6K1 and p-S6RP in RA versus controls (Fig. 7c,d) . By pretreating with the mTORC1 inhibitor rapamycin, we estimated that about 50% of p-S6RP in healthy T cells resulted directly from mTOR activation; in RA T cells, two-thirds of p-S6RP were rapamycin sensitive (Fig. 7a,b) .
To investigate whether NMT1 not only regulates AMPK activity, but also controls mTORC1 signaling, we repressed NMT1 expression in healthy CD4 + T cells (Fig. 7e,f) . NMT1 repression resulted in mTORC1 activation, measured by p-S6RP abundance. In parallel, we attempted to revert the mTORC1 hyperactivity in RA T cells by rescuing NMT1 function (Fig. 7g,h) . Forced NMT1 overexpression corrected p-S6RP concentrations in RA T cells.
AMPK opposes mTORC1 via multiple mechanisms [31] [32] [33] . We explored whether restoring AMPK function could suppress mTORC1 hyperactivity. To activate AMPK, we applied A769662, an allosteric AMPK activator that acts independently of the lysosome 16 and metformin, an indirect AMPK activator that depends on lysosomal pathways 34 . A769662 sharply reduced p-S6RP amounts in RA T cells (Fig. 7i,j) . p-S6RP concentrations were unchanged after metformin treatment, indicating persistent mTORC1 hyperactivity (Fig. 7i,j) . Pharmacologic inhibition of AMPK with Compound C increased p-S6RP, demonstrating mTORC1 activation ( Supplementary Fig. 7d ). Together, these data associated loss-of-function in AMPK signaling with a gain-of-function in mTORC1 signaling. NMT1 emerged as an upstream regulator for both nutrient sensors, mechanistically connecting lipid modification with energy homeostasis and T cell differentiation.
AMPK activation is tissue protective.
To determine whether suppressed AMPK and exuberant mTORC1 signaling influenced T cell differentiation, we compared frequencies of CD4 + T cells expressing T-bet, RORγ t, IFN-γ , and IL-17 after stimulation under non-polarizing conditions. RA T cells produced higher frequencies of T H 1committed effector cells, whereas IL-4-producing T H 2 cells were similar in all three study cohorts (Fig. 8a-f ). Mal-differentiation of naive CD4 + T cells into pro-inflammatory T H 1 and T H 17 cells was a feature exclusively for RA patients. Pharmacologic interference targeting AMPK with A769662 normalized frequencies of T-bet + and IFN-γ + T cells (Fig. 8g,h) ; metformin failed to oppose the differentiation bias of RA T cells.
To test whether forced AMPK activation translated into tissue protection in vivo, we explored A769662 treatment in the human-synovium chimera model ( Fig. 8i-l) . The chimeras tolerated A769662 well, without obvious toxic effects. A769662 treatment efficiently suppressed synovitis ( Fig. 8i-l) . The density of synovium-infiltrating T cells and of IFN-γ + tissue-resident T cells were reduced by > 50% (Fig. 8i-k) . A769662 therapy downregulated expression of T H 1-and T H 17-cell-associated genes (TBX21, RORC, IFNG, IL17A) and of those encoding innate inflammatory cytokines (TNF, IL1B, IL6) (Fig. 8l) . GATA3, IL4, and FOXP3 gene expression remained unaffected ( Supplementary Fig. 8a ).
A769662's anti-inflammatory effect was comparable to that of rapamycin. Rapamycin treatment in human-synovium-NSG chimeras efficiently reduced IFN-γ production of tissue-resident T cells (Fig. 8m-o) . Inflammation-related genes were highly sensitive to rapamycin-induced immunosuppression (Fig. 8p) . Conversely, tissue expression of T H 2 and regulatory T cell lineage markers were unaffected ( Supplementary Fig. 8b ). In vitro studies confirmed that activating AMPK with A769662 and inhibiting mTORC1 with rapamycin had equal potency to suppress pro-inflammatory T cells (Fig. 8g,h and Supplementary Fig. 8c ). Treatment with either A769662 or rapamycin normalized frequencies of T H 1 and T H 17 cells. Frequencies of CD4 + FoxP3 + T cells tripled in the presence of rapamycin ( Supplementary Fig. 8c ) and doubled in A769662-treated cultures ( Supplementary Fig. 8d ). Overall, these data connected the AMPK/mTORC1 balance to pro-inflammatory conditioning of adaptive immune responses, revealed the sensitivity of the pathway to pharmacotherapy, and identified the endomembrane placement of kinases as critical in therapeutic strategies.
Discussion
Cellular bioenergetics shape T cell effector functions and thus direct adaptive immune responses as exemplified in the autoimmune disease RA. Pathogenic T cells in RA patients have a distinctive metabolic signature, separating them from healthy activated T cells and from T cells in other inflammatory conditions, such as SLE 3, 8, 11 . RA T cells restrict glycolytic breakdown, freeing glucose for pentose phosphate pathway entry to supply NADPH and biosynthetic precursors. Excessive lipogenesis supports formation of invasive membrane structures, promoting tissue inflammation 5 . In search for upstream defects, we explored how such T cells monitor AMP/ATP ratios; the most sensitive variable used to adjust energy production to demand. We localized the primary defect to N-myristoyltransferase, a highly specific enzyme responsible for the co/post-translational modification of proteins by attaching the C-14 fatty acid myristate to the N-terminal glycine. Deficient N-fatty acylation markedly affected the subcellular distribution of AMPK, disrupting its translocation to membrane-bound compartments on lysosomal surfaces. Insufficient AMPK activation left mTORC1 activation unopposed, promoting cellular proliferation and progressive differentiation. Myristoylation-incompetent T cells favored IFN-γ and IL-17 production and drove tissue inflammation. T-cell-induced synovitis was preventable by NMT1 overexpression, identifying myristoylation as a tissue-protective mechanism.
Several lines of evidence provided clues for AMPK deficiency in RA T cells. AMPK inhibits fat synthesis and promotes fat oxidation 35, 36 . Yet, RA T cells accumulate lipid droplets, most probably as a result of insufficient mitochondrial β -oxidation 5 . AMPK signaling enhances mitochondrial biogenesis via regulating PGC1α and coordinating mitophagy via ULK1/2 15 . Reduced ATP in RA T cells should prompt AMPK activation, switching off ATP-consuming processes and promoting ATP generation. However, this feedback Articles NATuRe IMMuNOLOgy loop depends on the cell's ability to assign AMPK to relevant subcellular compartments. RA T cells retained the kinase in a diffuse cytoplasmic distribution, failing to anchor AMPK at lysosomal surfaces. Lysosomal recruitment embeds AMPK into the v-ATPase-Ragulator-LKB1-Axin super-complex, colocalizing it with mTORC1. Experiments using pharmacologic AMPK activators suggested additional extra-lysosomal activation sites for the kinase. Metformin failed to rescue AMPKα phosphorylation, in line with its proposed role in lysosome-dependent AMPK activation by inhibiting mitochondrial complex 1 34 . A769662-enforced AMPK activation did not require lysosomal docking. These data suggest multiple subcellular compartments enabling AMPK activation, opening opportunities for select therapeutic manipulations.
NMT1 influences a series of cellular signal transduction pathways by redirecting proteins from the soluble to the membranebound fraction. Interaction with calnexin retains NMT1 at the ER membrane 37 , close to proteins trafficking out of the ER. NMT1 regulates replication of human immunodeficiency virus 38 and determines cell-cycle progression and malignant growth of cancer cells 39 . The global N-myristoylated proteome in human cells includes more than 100 proteins 40 . Most of the myristoylated proteins are undefined, suggesting that the NMT1 lo RA T cells may have abnormalities beyond AMPK misdistribution. Being shorter than palmitoyl groups, myristoyl groups promote weaker and reversible membrane-protein interactions, but AMPK's spatiotemporal distribution seems particularly sensitive to this co/post-translational 
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modification. AMPK's myristate tail was first described more than two decades ago, predicting that the kinase would position at endomembranes. Besides guiding the enzyme to lysosomes, the lipidic modification has also been implicated in non-canonical AMPK functions. Mitochondrial translocation of AMPK regulates mitophagy and cellular survival 41 . The NMTs are overexpressed in malignant cells and are possible therapeutic targets in cancer treatment. Conversely, autoimmune tissue inflammation appears associated with deficient NMT1 function, assigning a tissue-protective role to this transferase. Deficient N-myristoylation markedly affected T cell differentiation. Loss-of-function and gain-of-function experiments mechanistically connected lineage commitment to the pro-inflammatory T H 1 and T H 17 lineages with NMT1 abundance. In vivo, siRNAmediated NMT1 knockdown induced accumulation of tissue T H 1 and T H 17 cells. NMT1 overexpression in spontaneously NMT1 lo RA T cells was strongly anti-inflammatory. T cell mal-differentiation was amendable to pharmacologic AMPK activation and resulted from excessive activation of the mTORC1 kinase. The activation status of mTORC1 was tightly connected to AMPK activation. Given that mTORC1 is responsible for promoting cellular growth 42 , mTORC1 activation would only seem appropriate under conditions of energy surplus, when AMPK is deactivated. RA T cells break this rule and hyper-proliferate despite low intracellular ATP pools.
The current study has immediate clinical consequences, including a more refined understanding of how metabolic reprogramming, cellular protein trafficking, and tissue inflammation are interlinked. Data presented will allow the identification of therapeutic targets to hinder the uncontrolled expansion of energy-deprived and arthritogenic T cells. By monitoring AMPK's activation state, predictions can be made about inflammatory propensity, providing a useful screening system for potential therapeutic agents. The current study tested three small molecule reagents. Metformin, a lysosomal AMPK activator widely applied to manage type 2 diabetes mellitus and believed to have anti-inflammatory activity 43, 44 , failed to revert AMPK mislocalization; consistent with the minimal antiinflammatory effects in autoimmune disease 45 . The direct AMPK activator A769662 16, 46 proved effective in preventing T cell mal-differentiation and tissue inflammation in vivo. The most successful intervention directly targeted mTORC1; rapamycin was potently anti-inflammatory, confirming recent reports that rapamycin is an effective disease-modulatory therapy in SLE 47, 48 . However, mTORC1 inhibition cannot restore AMPK's N-myristoylation, achievable only by restoring the expression of functionally intact NMT1.
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